Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
|Videos|March 14, 2011
Advances in Kidney Cancer Over the Past Several Years
Author(s)Ana M. Molina, MD
Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years
Advertisement
Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years
Advertisement
Related to this article
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5